Bath & Body Works (NYSE:BBWI) Price Target Raised to $25.00 at TD Cowen

Bath & Body Works (NYSE:BBWI) had its price target increased by investment analysts at TD Cowen from $20.00 to $25.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s price objective suggests a potential upside of 25.36% from the stock’s current price.

A number of other research analysts also recently commented on BBWI. Barclays lowered their target price on Bath & Body Works from $25.00 to $23.00 and set an “equal weight” rating on the stock in a research note on Thursday. Citigroup downgraded Bath & Body Works from a “buy” rating to a “neutral” rating and upped their price target for the stock from $21.00 to $25.00 in a research note on Tuesday, February 17th. Telsey Advisory Group decreased their price target on Bath & Body Works from $25.00 to $22.00 and set a “market perform” rating for the company in a research note on Thursday. Wells Fargo & Company decreased their price target on Bath & Body Works from $29.00 to $25.00 and set an “overweight” rating for the company in a research note on Thursday. Finally, The Goldman Sachs Group decreased their price target on Bath & Body Works from $26.00 to $23.00 and set a “neutral” rating for the company in a research note on Thursday. Three investment analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $21.93.

Bath & Body Works Stock Performance

Shares of BBWI stock traded up $0.49 on Thursday, reaching $19.94. 1,638,062 shares of the company’s stock traded hands, compared to its average volume of 5,725,187. Bath & Body Works has a 12-month low of $14.27 and a 12-month high of $33.96. The company has a market capitalization of $4.02 billion, a P/E ratio of 6.34, a price-to-earnings-growth ratio of 1.76 and a beta of 1.43. The business’s 50 day moving average price is $18.65 and its two-hundred day moving average price is $20.24.

Bath & Body Works (NYSE:BBWI) last issued its quarterly earnings results on Wednesday, May 27th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.03. Bath & Body Works had a negative return on equity of 45.60% and a net margin of 8.90%.The business had revenue of $1.38 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the previous year, the company posted $0.49 earnings per share. Bath & Body Works’s revenue for the quarter was down 3.2% compared to the same quarter last year. Bath & Body Works has set its Q2 2026 guidance at 0.300-0.300 EPS and its FY 2026 guidance at 2.400-2.650 EPS. Research analysts predict that Bath & Body Works will post 2.61 earnings per share for the current year.

Hedge Funds Weigh In On Bath & Body Works

A number of hedge funds have recently modified their holdings of BBWI. Global Retirement Partners LLC acquired a new position in shares of Bath & Body Works in the 4th quarter worth approximately $31,000. Activest Wealth Management acquired a new position in Bath & Body Works in the fourth quarter valued at about $32,000. Geneos Wealth Management Inc. boosted its position in Bath & Body Works by 217.7% in the first quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock valued at $35,000 after buying an additional 801 shares in the last quarter. Parallel Advisors LLC boosted its position in Bath & Body Works by 42.6% in the fourth quarter. Parallel Advisors LLC now owns 1,897 shares of the company’s stock valued at $38,000 after buying an additional 567 shares in the last quarter. Finally, Danske Bank A S acquired a new position in Bath & Body Works in the third quarter valued at about $39,000. 95.14% of the stock is owned by institutional investors and hedge funds.

Bath & Body Works News Summary

Here are the key news stories impacting Bath & Body Works this week:

• Positive Sentiment: Bath & Body Works beat Q1 earnings and sales expectations, with results coming in above guidance and helping drive renewed investor confidence.
• Positive Sentiment: The company reaffirmed its full-year outlook, easing fears that the business was deteriorating faster than expected.
• Positive Sentiment: Analyst and market commentary highlighted valuation support and possible growth catalysts, including expansion opportunities and dividend appeal.
• Neutral Sentiment: Brokerages remain cautious overall, with consensus still centered around a “Hold” rating after recent updates.
• Negative Sentiment: Revenue remains under pressure, with Q1 sales down year over year as Bath & Body Works continues its turnaround effort.
• Negative Sentiment: Price target cuts from Goldman Sachs and Telsey Advisory Group suggest analysts are still tempering expectations for near-term upside.

About Bath & Body Works

Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.

Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.